NewsBenzingaDan Ives affirme qu’Anthropic pourrait finir par valoir 3 000 milliards de dollars malgré sa perte de 80,7 milliards de dollars — et insiste sur le fait que la révolution de l’IA n’en est encore qu’à sa « troisième manche » Dan Ives affirme qu’Anthropic pourrait finir par valoir 3 000 milliards de dollars malgré sa perte de 80,7 milliards de dollars — et insiste sur le fait que la révolution de l’IA n’en est encore qu’à sa « troisième manche » Benzinga 2026.10.27 09:21 (GMT+0) Open on Benzinga Other news Cadence Design Analysts Boost Their Forecasts Following Upbeat Q3 Earnings S&P Global Explores Alternatives For Capital IQ, Associated Data Operations AptarGroup's Pharma Unit Partners With Stevanato Group To Provide System-Level Data Supporting Earlier Evaluation Of Pre-Filled Syringe Configurations S&P Global Lowers FY2026 GAAP EPS Guidance from $16.35-$16.60 to $16.25 vs $16.03 Est; Raises FY2026 Sales Guidance from $16.302B-$16.609B to $16.471B-$16.624B S&P Global Raises FY2026 Adj EPS Guidance from $17.50-$17.75 to $17.70-$17.95 vs $17.89 Est; Sees Sales $16.471B-$16.624B vs $14.788B Est Wolfe Research Assumes U.S. Bancorp at Peer Perform
AptarGroup's Pharma Unit Partners With Stevanato Group To Provide System-Level Data Supporting Earlier Evaluation Of Pre-Filled Syringe Configurations
S&P Global Lowers FY2026 GAAP EPS Guidance from $16.35-$16.60 to $16.25 vs $16.03 Est; Raises FY2026 Sales Guidance from $16.302B-$16.609B to $16.471B-$16.624B
S&P Global Raises FY2026 Adj EPS Guidance from $17.50-$17.75 to $17.70-$17.95 vs $17.89 Est; Sees Sales $16.471B-$16.624B vs $14.788B Est